Company ESSA Pharma Inc.

Equities

EPIX

CA29668H7085

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
6.95 ^USD	+4.98%		+13.56%	+5.30%

03-06	Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call
03-06	Norway's wealth fund pushes for more women on emerging market company boards	RE

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.

Number of employees: 50

Managers	Title	Age	Since
David Parkinson CEO	Chief Executive Officer	73	23/06/15
David Wood DFI	Director of Finance/CFO	66	30/09/13
Peter Virsik COO	Chief Operating Officer	-	31/07/16
Alessandra Cesano CTO	Chief Tech/Sci/R&D Officer	63	14/07/19

Members of the board	Title	Age	Since
Franklin Berger BRD	Director/Board Member	74	04/03/15
Sanford Zweifach BRD	Director/Board Member	68	30/07/19
Richard Glickman CHM	Chairman	65	30/09/10
Alex Martin Martin BRD	Director/Board Member	55	30/07/19
Scott Requadt BRD	Director/Board Member	56	13/01/16
David Parkinson CEO	Chief Executive Officer	73	23/06/15
Philip Kantoff BRD	Director/Board Member	69	12/09/22
Ann Thorell BRD	Director/Board Member	56	30/07/19
Gary Sollis BRD	Director/Board Member	69	25/04/12
Lauren Merendino BRD	Director/Board Member	49	05/06/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	44,238,147	43,230,299 ( 97.72 %)	0	97.72 %

Name	Equities	%	Valuation
BVF, Inc. 19.78 %	8,748,629	19.78 %	74 M $
Bellevue Asset Management AG 17.85 %	7,898,583	17.85 %	67 M $
Soleus Capital Management LP 9.783 %	4,327,622	9.783 %	37 M $
Morgan Stanley Capital Services LLC 9.464 %	4,186,578	9.464 %	36 M $
PFM Health Sciences LP 7.375 %	3,262,500	7.375 %	28 M $
RTW Investments LP 5.196 %	2,298,662	5.196 %	20 M $
Adage Capital Partners GP LLC 2.568 %	1,135,931	2.568 %	10 M $
Janus Henderson Investors US LLC 2.463 %	1,089,482	2.463 %	9 M $
Franklin Berger 1.773 %	784,404	1.773 %	7 M $
Rock Springs Capital Management LP 1.530 %	677,005	1.530 %	6 M $

ESSA Pharma, Inc.

999 West Broadway Suite 720

V5Z 1K5, Vancouver

http://www.essapharma.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.524 CAD

Average target price

26.63 CAD

Spread / Average Target

+179.64%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ESSA PHARMA INC.	+5.30%	307M
MODERNA, INC.	+26.28%	48.09B
IQVIA HOLDINGS INC.	-3.99%	40.43B
LONZA GROUP AG	+46.85%	40.62B
CELLTRION, INC.	-6.20%	28.36B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.89B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.01B
MEDPACE HOLDINGS, INC.	+27.58%	12.09B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.8B
BIO-TECHNE CORPORATION	-2.02%	11.88B

Other Biotechnology & Medical Research